Daniel Egle

Epigenetic stem cell signature in cancer

Martin Widschwendter, Heidi Fiegl, Daniel Egle et al. · Nature Genetics · 2006 · 1.2K citations

Medicine, Cancer Biology, Oncology +12

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial

Michael Gnant, Georg Pfeiler, Peter Dubsky et al. · The Lancet · 2015 · 560 citations

Medicine, Oncology, Pharmacology +13

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

Luca Gianni, Chiun‐Sheng Huang, Daniel Egle et al. · Annals of Oncology · 2022 · 386 citations · Full text

Medicine, Oncology, Pharmacology +15

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

Angelo Di Leo, Stephen Johnston, Keun Seok Lee et al. · The Lancet Oncology · 2017 · 381 citations

Medicine, Oncology, Pharmacology +16

Spatial predictors of immunotherapy response in triple-negative breast cancer

Xiao Qian Wang, Esther Danenberg, Chiun‐Sheng Huang et al. · Nature · 2023 · 325 citations · Full text

Medicine, Immunology, Oncology +17